424 related articles for article (PubMed ID: 8972476)
21. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
[TBL] [Abstract][Full Text] [Related]
24. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.
Holcomb K; Delatorre R; Pedemonte B; McLeod C; Anderson L; Chambers J
Obstet Gynecol; 2002 Dec; 100(6):1290-5. PubMed ID: 12468176
[TBL] [Abstract][Full Text] [Related]
25. GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma.
Idrees MT; Schlosshauer P; Li G; Burstein DE
Histopathology; 2006 Jul; 49(1):75-81. PubMed ID: 16842248
[TBL] [Abstract][Full Text] [Related]
26. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
27. [Serous adenocarcinoma of the uterus: criteria of morphological diagnosis and immunohistochemistry].
Vasil'eva EV; Belianin VL
Arkh Patol; 2005; 67(2):25-7. PubMed ID: 15938115
[TBL] [Abstract][Full Text] [Related]
28. Loss of p53 function in uterine papillary serous carcinoma.
Kovalev S; Marchenko ND; Gugliotta BG; Chalas E; Chumas J; Moll UM
Hum Pathol; 1998 Jun; 29(6):613-9. PubMed ID: 9635683
[TBL] [Abstract][Full Text] [Related]
29. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.
Bancher-Todesca D; Gitsch G; Williams KE; Kohlberger P; Neunteufel W; Obermair A; Heinze G; Breitenecker G; Hacker NF
Gynecol Oncol; 1998 Oct; 71(1):59-63. PubMed ID: 9784320
[TBL] [Abstract][Full Text] [Related]
30. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
[TBL] [Abstract][Full Text] [Related]
31. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
[TBL] [Abstract][Full Text] [Related]
32. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
33. p53 as a prognostic indicator in endometrial cancer.
Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
Gynecol Oncol; 1996 May; 61(2):245-8. PubMed ID: 8626141
[TBL] [Abstract][Full Text] [Related]
34. BCL-2 and P53 expression in endometrial carcinoma.
Erkanli S; Eren F; Pekin S; Bagis T
J Exp Clin Cancer Res; 2004 Mar; 23(1):97-103. PubMed ID: 15149157
[TBL] [Abstract][Full Text] [Related]
35. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
36. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
37. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas.
Harlozińska A; Bar J; Montenarh M
Anticancer Res; 2000; 20(2A):1049-56. PubMed ID: 10810396
[TBL] [Abstract][Full Text] [Related]
39. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic implications of p16 expression in serous papillary endometrial cancer.
Netzer IM; Kerner H; Litwin L; Lowenstein L; Amit A
Int J Gynecol Cancer; 2011 Nov; 21(8):1441-5. PubMed ID: 22027748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]